| Trial ID: | L3137 |
| Source ID: | NCT02089126
|
| Associated Drug: |
Gemigliptin/Glimepiride Combination
|
| Title: |
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Gemigliptin/Glimepiride combination
|
| Outcome Measures: |
Primary: HbA1c Changes, Week 0, Week 24 |
|
| Sponsor/Collaborators: |
Sponsor: LG Life Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
230
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-06
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2014-03-17
|
| Locations: |
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02089126
|
